| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,896 |
1,758 |
$86K |
| 62323 |
|
409 |
385 |
$52K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,696 |
1,620 |
$46K |
| L0651 |
Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf |
58 |
46 |
$33K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
877 |
821 |
$26K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
128 |
125 |
$10K |
| 64635 |
|
24 |
15 |
$5K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
434 |
408 |
$3K |
| 99406 |
|
328 |
302 |
$3K |
| 64636 |
|
25 |
14 |
$3K |
| 99215 |
Prolong outpt/office vis |
55 |
49 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
30 |
29 |
$2K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
12 |
12 |
$532.39 |
| 99490 |
Ccm add 20min |
66 |
64 |
$434.22 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
131 |
120 |
$228.73 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
74 |
69 |
$64.92 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,096 |
1,017 |
$0.00 |
| G9500 |
Radiation exposure indices documented in final report for procedure using fluoroscopy |
984 |
897 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
1,990 |
1,872 |
$0.00 |
| 3725F |
|
579 |
564 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
715 |
687 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,885 |
1,765 |
$0.00 |
| 3085F |
|
1,113 |
1,063 |
$0.00 |
| 98960 |
|
327 |
322 |
$0.00 |